Background And Aims: Oncogenic KRAS mutations are present in approximately 90% of pancreatic ductal adenocarcinoma (PDAC). However, Kras mutation alone is insufficient to transform precancerous cells into metastatic PDAC. This study investigates how KRAS-mutated epithelial cells acquire the capacity to escape senescence or even immune clearance, thereby progressing to advanced PDAC.
Methods: Single-cell RNA sequencing and analysis of primary PDAC tumors were conducted. Genetically engineered pancreas-specific Kras-mutated, dual specificity phosphatase-2 (Dusp2) knockout mouse models were established. Human and mouse primary pancreatic cancer cell lines were used for in vitro assessment of cancer characteristics. Tumor progression was studied via pancreas orthotopic and portal vein injection in the immune-competent mice. Clinical relevance was validated by digital spatial transcriptomic analysis of PDAC tumors.
Results: Kras mutation induces the formation of pancreatic intraepithelial neoplasia (PanIN), these lesions also exhibit significant apoptotic signals. Single-cell RNA sequencing identified a subset of ERKDUSP2 cells continuing to expand from early to advanced stage PDAC. In vitro and in vivo studies reveal that early infiltrating macrophage-derived tissue inhibitor of metallopeptidase 1 (TIMP-1) is the key factor in maintaining the ERKDUSP2 cell population in a CD63-dependent manner. The ERKDUSP2 cancer cells further exacerbate macrophage-mediated cancer malignancy, including loss of epithelial trait, increased lymphangiogenesis, and immune escape. Digital spatial profiling analysis of PDAC samples demonstrates the colocalization of TIMP-1 macrophages and CD63 cancer cells. The presence of TIMP-1 macrophages and CD63 epithelial cells correlates with poor prognosis in PDAC.
Conclusions: Our study reveals the vicious cycle between early infiltrating macrophages and pancreatic cancer cells, providing a mechanistic insight into the dynamic regulation directing pancreatic cancer progression.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742192 | PMC |
http://dx.doi.org/10.1186/s12943-024-02207-4 | DOI Listing |
Sci Rep
January 2025
First Department of Medicine, Medical School, University of Pécs, Ifjúság Útja 13, 7624, Pécs, Hungary.
Both acute kidney injury and chronic kidney disease are risk factors for many outcomes of gastrointestinal bleeding (GIB). These are associated with higher mortality, longer hospitalisation, and greater need for transfusion in case of overt GIB. Our study aimed to further evaluate the role of kidney function in several clinical outcomes of GIB patients.
View Article and Find Full Text PDFBackground: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a 5-year survival rate of 12%. It has two major molecular subtypes: classical and basal, regulated by the master transcription factors (MTFs) GATA6 and ΔNp63, respectively.
Objective: This study sought to uncover the transcriptional regulatory mechanisms controlling PDAC subtype identity.
Phys Med Biol
January 2025
Department of Radiation Oncology, Division of Medical Physics and Engineering , UT Southwestern Medical Center, 2280 Inwood Road, Dallas, Texas, 75390-9096, UNITED STATES.
One bottleneck of MRI-guided Online Adaptive Radiotherapy (MRoART) is the time-consuming daily online replanning process. The current leaf sequencing method takes up to 10 minutes, with potential dosimetric degradation and small segment openings that increase delivery time. This work aims to replace this process with a fast deep learning-based method to provide deliverable MLC sequences almost instantaneously, potentially accelerating and enhancing online adaption.
View Article and Find Full Text PDFJCO Glob Oncol
January 2025
Adults Solid Tumors Chemotherapy Department, Yeolyan Hematology and Oncology Center, Yerevan, Armenia.
Purpose: Pancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.
View Article and Find Full Text PDFPLoS One
January 2025
Cell Therapy Center, The University of Jordan, Amman, Jordan.
Background: Hypoxia in tumor cells is linked to increased drug resistance and more aggressive behavior. In pancreatic cancer, the tumor microenvironment is notably hypoxic and exhibits strong immunosuppressive properties. Given that immunotherapy is now approved for pancreatic cancer treatment, further understanding of how pancreatic tumor cell hypoxia influences T-cell cytotoxicityis essential.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!